Banco Santander (SAN)
(Delayed Data from NYSE)
$5.11 USD
+0.05 (0.99%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.11 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth A Momentum C VGM
Price, Consensus and EPS Surprise
SAN 5.11 +0.05(0.99%)
Will SAN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SAN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SAN
SAN vs. HDB: Which Stock Is the Better Value Option?
Are Investors Undervaluing Banco Santander (SAN) Right Now?
SAN: What are Zacks experts saying now?
Zacks Private Portfolio Services
HSBC Gets Russia Unit Sale Approval, Paves Way for Full Exit
SAN or SMFG: Which Is the Better Value Stock Right Now?
Is Banco Santander (SAN) Stock Undervalued Right Now?
Other News for SAN
Kepler Capital Keeps Their Hold Rating on Sanofi (SNYNF)
SobiĀ® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
GLOBAL BROKER RATINGS: Stifel cuts Caterpillar; HSBC likes Ashtead
Banco Santander Advances Share Buyback Program
TOP NEWS: Sanofi in "excellent" start to 2024 as Dupixent sales jump